Gastric cancer Gastric cancer, peritoneal metastasis
Conditions
Interventions
Paclitaxel is administered intraperitoneally at 20 mg/m2 on days 1,8 and 22. S-1 is administered at 80 mg/m2/day for 21 consecutive days, followed by 14 days-rest.
Cisplatin is administered at 60 mg/
Sponsors
Kodera Yasuhiro
Kitayama Jyoji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven unresectable or recurrent gastric adenocarcinoma 2) Peritoneal metastasis 3) No prior chemotherapy 4) Adequate bone marrow function 5) Eastern Cooperative Oncology Group performance status 0-1 6) An expected survival period of more than 3 months 7) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Metastasis to distant organ sites (such as the liver, lungs or bone) 2) Other active concomitant malignancies 3) other severe medical conditions; pregnant 4) unwilling to practice contraception during the study, or lactating female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, time to treatment failure, response rate, negative conversion rate on peritoneal cytology, safety, 2-year overall survival rate, 3-year overall survival rate | — |
Contacts
Public ContactDaisuke Kobayashi
Nagoya University Hospital
Outcome results
None listed